Letter to the Editor: Chronic Kidney Disease - a Neglected Disease in the Economic Conditions Burden Analysis in Korea

We appreciate the wide range of 238 disease and 22 injury coverage and the important related estimates of economic burden of these conditions in Korea produced Lee et al.1 However, we would like to underline the important shortcoming in estimates of chronic kidney disease (CKD) burden. The authors reported cost of top-20 conditions, in which the alcohol use disorders ranked 20th with 1.9 billion USD total cost in 2015 (as reflected at Fig. 2). The available literature evidence suggests the burden of CKD far exceeds this threshold, and thus it has to be presented among the top diseases having highest burden in Korea.

In December 2015 in the South Korea there were 87,014 patients receiving renal replacement therapy (RRT),2 which had exceptionally high treatment cost.3 Among all RRT patients there were 62,634 individuals receiving hemodialysis, 7,352 individuals treated by peritoneal dialysis, and 17,028 individuals with functioning kidney graft2 with estimated direct cost 34,554 Euro (39,046 USD), 25,806 Euro (29,160 USD), and 35,765 Euro (40,414 USD) per one year of treatment, respectively.3 Calculations with aforementioned numbers suggest that only direct cost of RRT treatment claimed to 3.3 billion USD. Among a whole spectrum of kidney diseases, the RRT represents only relatively small fraction of therapy for the most advanced stages. However, the earlier CKD stages (i.e., CKD stages 1-4 not requiring RRT) are much more prevalent, and being reported in 7.9% of adult participants of the fifth Korean National Health and Nutrition Examination Survey.4 In a nation-wide scale this percentage could be extrapolated to almost 3.2 million individuals with CKD, and the Korean National Health Insurance statistical Yearbook reported almost 160,000 hospital visits due to CKD in 2014.5 Direct cost for CKD stage 3 was estimated as 1,205 Euro (1,361 USD), and for CKD stage 4 as 1,962 Euro (2,217 USD) per year,3 while there are no published cost estimates of management for patients with even earlier CKD stages defined by detection of albuminuria only and grade 1 or 2 of glomerular filtration rate.

The aforementioned available data suggest the total annual cost of CKD far exceeds 5 billion USD, and thus should be reflected among the top ranked disease in Korea. We believe that accounting chronic kidney disease among the priorities of public health agenda is crucial for applying effective prevention and treatment strategies, and would suggest to consider high burden of CKD in the economic health analysis performed in Korea or in any other country.